Eurofarma partnership with Korean Dong-A

One of the largest national laboratories and third in the ranking of generic industry of Brazil, Eurofarma took another step in its internationalization and consolidation plan as regional pharmaceutical, through a partnership with the South Korean lab Dong-a.
With a presence in 15 countries and exports to 20 markets, the Brazilian company has printed fast pace for the purchase of assets, particularly in Latin America, and the signing of international agreements that include technology transfer.
This time, while released in country a medicine for erectile dysfunction treatment developed by Dong-A, Eurofarma extended co-development and marketing agreement evogliptina drug, used in patients with diabetes, signed with the South Korean lab and originally valid for the Brazilian market, for 17 countries of Latin America more.
"There are discussions with Dong-A concerning more medicines. This is a partnership that should last a long time, "said to the Vice President of research and innovation of the company, Martha Penna. Preliminary results of the study with the evogliptina proved the effectiveness of the new molecule, second Eurofarma, phase 3 of the research in the country. The expectation is that the drug is available in Brazil in 2021.
Since 2009, when bought argentina Quesada, Eurofarma has closed the acquisition of a number of pharmaceutical and manufacturing operations in Uruguay, Bolivia, Chile, Venezuela and Colombia, among other countries in the region. As a result of the investee, the Brazilian struck in 2014, 78.4% coverage of the Latin American market, according to data from IMS Health. And, by the end of this year, Eurofarma is intended to reach 90% of the region, whose pharmaceutical market moved $ 71 billion last year.
The partnership with Dong-A also represents another of the series of agreements signed by the Brazilian pharmaceutical under development in the area of radical innovation, which involves the search for new molecules, with technology transfer to local production.
According to Martha, the new drug, DPP4 inhibitors class, brings advances in order to present little interaction with other medications commonly used by patients with diabetes and to dispense with the dose adjustment in those who present with kidney failure, which must be proven in phase 3 which will start in the country in 2015.
Last year, Eurofarma grossed r $ 2.6 billion and recorded high of 17.4% in exports. The Costa Rica was the main export destination of the company, especially also for Paraguay, Viet Nam, Chile, Ecuador and Panama. This account does not include shipments to meet international operations, which accounted for 10.1% of 2014 in the company's business.